Melbourne, – A new treatment option for anaphylaxis is now available in Australia with the approval of neffy® adrenaline (epinephrine) nasal spray. CSL Seqirus announced today that the needle-free nasal spray is approved for the emergency treatment of anaphylaxis in adults and children weighing 15kg or more, and aged four years and over.
Anaphylaxis is a severe and potentially life-threatening allergic reaction triggered by exposure to allergens such as foods, medications, and insect stings. It requires immediate treatment with adrenaline to reverse symptoms like throat swelling, difficulty breathing, and a drop in blood pressure.3
Australia has seen a concerning rise in anaphylaxis cases in recent years. Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalizations due to anaphylaxis.6,7 This makes Australia one of the countries with the highest documented rates of anaphylactic episodes in the developed world.5
“The approval of neffy is very welcome as it gives patients and their doctors a nasal administration option and choice in managing their condition,” says Professor Connie Katelaris AM, a leading allergist in New South Wales. “It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia.”
neffy offers a different delivery method compared to traditional epinephrine auto-injectors. The nasal spray delivers epinephrine directly into the nostril, offering a needle-free alternative. The medication temporarily loosens the spaces between nasal cells, allowing for rapid absorption.1
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, emphasized the broad impact of anaphylaxis. “Having a new treatment option which does not require injection will offer people at risk of anaphylaxis, and their treating doctor, the ability to choose an adrenaline device that best suits their needs from the range available,” she stated. She also highlighted the constant vigilance required by those with allergies and their families, noting the need for careful planning around everyday activities like dining out, attending social events, and school activities.
Dr. Jonathan Anderson, Executive Medical Director – International and GP at CSL Seqirus, expressed pride in the company’s role in bringing neffy to the Australian market. “This is an important treatment option and so today is a proud day for CSL Seqirus as an Australian company,” he said. He also indicated the company’s commitment to expanding access to the treatment and working with decision-makers to secure funding for inclusion on the Pharmaceutical Benefits Scheme (PBS).
Currently, neffy is not listed on the PBS. CSL Seqirus has submitted an application for subsidy, which will be reviewed in March 2026.1
Healthcare organizations are updating their resources and anaphylaxis education materials to include information about neffy.
Important Information About neffy
neffy is a prescription medicine and should be used at the first signs or symptoms of anaphylaxis. Following administration, patients should seek immediate emergency medical attention for monitoring and potential further treatment. The product consists of two single-dose nasal spray devices, with a second dose potentially needed if symptoms persist or worsen, administered five minutes after the first dose.1
Common side effects reported with neffy include headache, nasal discomfort, throat irritation, and feeling jittery.1
Understanding Anaphylaxis
Anaphylaxis is the most severe type of allergic reaction, affecting multiple body systems including the skin, respiratory system, gastrointestinal tract, and cardiovascular system.3 Symptoms can include difficulty breathing, swelling of the tongue or throat, wheezing, dizziness, and in young children, paleness and floppiness.3
Resources for Patients and Families
Allergy & Anaphylaxis Australia is a national patient support organization providing information and resources for individuals and families managing allergic disease. Allergy250K offers age-appropriate information and support for young people living with severe allergies.
About CSL Seqirus
CSL Seqirus, part of CSL Limited, is a global leader in influenza vaccine production and a significant contributor to pandemic preparedness. The company also manufactures a range of other essential medicines in Australia, including antivenoms and vaccines.
- neffy approved Consumer Medicine Information: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2025-CMI-02437-1&d=20251218172310101
- ARTG. 2025. Available at: https://www.tga.gov.au/resources/artg/42978. Accessed October 2025.
- ASCIA. Analphylaxis Fast Facts. Available at: https://www.allergy.org.au/patients/fast-facts/anaphylaxis. Accessed February 2026.
- Parliament of the Commonwealth of Australia. 2020. Available at: https://parlinfo.aph.gov.au/parlInfo/download/committees/reportrep/024422/toc_pdf/Walkingtheallergytightrope.pdf;fileType=application%2Fpdf. Accessed October 2025.
- Mullins RJ, et al. Clin Exp Allergy. 2016;46;1099–1110.
- Australian Commission on Safety and Quality in Health Care. 2021. Available at: https://www.safetyandquality.gov.au/standards/clinical-care-standards/acute-anaphylaxis-clinical-care-standard. Accessed October 2025.
- ASCIA. 2023. Available at: https://www.allergy.org.au/hp/papers/acute-management-of-anaphylaxis-guidelines. Accessed October 2025.
